Otonomy Inc. buy melinda
Start price
30.08.17
/
50%
€3.49
Target price
13.11.17
€6.31
Performance (%)
33.23%
End price
13.11.17
€4.65
Summary
This prediction ended on 13.11.17 with a price of €4.65. The BUY prediction by melinda for Otonomy Inc. saw massive gains of 33.23%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Otonomy Inc. | - | - | - | - |
| iShares Core DAX® | 0.855% | 0.389% | 2.533% | 52.003% |
| iShares Nasdaq 100 | -0.989% | -4.400% | 25.154% | 77.536% |
| iShares Nikkei 225® | -1.781% | -11.216% | 44.398% | 64.676% |
| iShares S&P 500 | 0.057% | 0.778% | 20.953% | 63.009% |
Comments by melinda for this prediction
In the thread Otonomy Inc. diskutieren
Hersteller von Arzneimitteln
30. August (Reuters) - US - Arzneimittelhersteller Otonomy Inc. sagte am Mittwoch , dass seine Droge Meniere-Krankheit, eine chronische Erkrankung des Innenohrs zu behandeln, das Hauptziel in einer späten Studie fehlt.